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This article reviews topics covered and discussed at the Meeting: 
“Vaccini e vaccinazioni. Migliorare l’oggi e preparare il domani”, 
held in Genoa, Italy, on 12 September 2014. Data presented at 
the meeting, clearly showed that: 1) hepatitis B vaccination can 
confer long-term protection and there is no need for booster in 
immunocompetent vaccinees; 2) vaccination is highly effective in 
protecting population from clinical acute or chronic HBV infec-
tions, including hepatocellular carcinoma; 3) children vaccinated 
as infants with hexavalent vaccines maintain immunological mem-
ory 5 years after priming, but further studies are needed to assess 
whether immunity persists during the adolescence and adulthood 
when risk of exposure to HBV becomes higher; 4) the emergence 
of vaccine-escape mutants and Pol-gene mutants during antiviral 
therapy – which can result in changes in the S-gene – is of some 
concern, but at present there is no evidence that such mutants may 
pose a threat to the established programs of vaccination.
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Summary
Introduction
Viral hepatitis B is a serious health problem throughout 
the world, being a leading cause of acute and chronic liv-
er disease including cirrhosis and primary liver cancer, 
which ranks as the 3rd cause of cancer deaths worldwide. 
Globally, over 350 million people are chronic carriers 
of hepatitis B virus (HBV), more than 500,000 die each 
year from HBV-related diseases, and approximately 4.5 
million people are newly infected yearly. The good news 
is that hepatitis B is now considered a largely treatable 
and preventable disease thanks to the availability of ef-
fective antiviral drugs and the implementation of several 
public health measures, including vaccination. Effective 
vaccines have been available since the early ’80s and 
have proved highly successful to control and prevent 
hepatitis B and its severe sequelae. Following WHO 
recommendations, at present 181 countries in the world 
have implemented programs of hepatitis B vaccination 
with success both in term of safety and effectiveness.
This article reviews topics covered and discussed at the 
“Vaccini e vaccinazioni. Migliorare l’oggi e preparare il 
domani” Meeting held in Genoa, Italy, on 12 September 
2014.
Is a booster dose of hepatitis B vaccine 
required to maintain long-term protection?
Hepatitis B vaccination has been administered to hun-
dreds of milion people of all ages showing an excellent 
level of safety and effectiveness in protecting people from 
developing clinical acute or chronic HBV infection. Fol-
lowing a complete course of vaccination (3 doses given 
at 0, 1, and 6 months), seroprotection rates (anti-HBs 
antibody at level  ≥  10 mIU/ml) are reached in > 95% 
of healthy children and adolescents, and in  >  90% of 
healthy adults. Evidence shows that hepatitis B vaccine-
induced anti-HBs antibody concentration declines over 
time and that the kinetics of decay depends on the mag-
nitude of the peak antibody level achieved after primary 
immunization. In other words, the higher is the titer after 
primary vaccination course, the longer the antibody per-
sists. Loss of protective antibody over time does neces-
sarily means loss of protection since the immunological 
memory for HBsAg (hepatitis B surface antigen) can 
outlast the presence of antibody. Indeed, memory B and 
T cells are likely to persist beyond detectable anti-HBs 
antibody. Vaccinees who lost antibody usually show a 
rapid and strong anamnestic response when boosted or 
exposed to HBV [1-5].
These data clearly indicate that a strong immunologi-
cal memory persists more than 20 years after primary 
immunization providing protection against clinical dis-
ease and the development of the carrier state [6-8]. Thus, 
based on current scientific evidence there is no need to 
administer booster doses of vaccine to sustain long-term 
protection in the general population. Such conclusion 
is based on data collected during the past 15-20 years 
and applies to both low and hyper-endemic areas of the 
world.
However, a booster dose could be provided to non- re-
sponders and some “at risk groups” (e.g., health care 
workers and immunocompromised individuals).
Recently, an increased number of failures to develop a 
response following a booster dose (the so-called boost-
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ability) has been reported in some Asiatic countries. 
Waining of the ability to respond a booster dose seems 
to be more frequent in individuals vaccinated at birth 
with poor responses to priming.
Surveillance and additional follow up are needed to clar-
ify this issue. 
Do children immunized as infants  
with hexavalent vaccines maintain 
protection over time?
In 2000, two hexavalent vaccines (Hexavac and Infanrix 
Hexa) were licensed in Europe for vaccinating children 
against diphtheria, tetanus, pertussis, poliomyelitis, hep-
atitis B and invasive infections caused by Haemophylus 
influenzae b. In 2005, Hexavac was suspended as a pre-
cautionary measure due to concern about long-term pro-
tection against hepatitis B, while no actions were taken 
over Infanrix Hexa [9]. Until suspension, approximately 
10 million doses of Hexavac had been distributed glob-
ally, especially in Germany, Austria, and Italy. A crucial 
question is whether infants vaccinated with Hexavac 
maintain protection over time or require a booster vac-
cination to sustain immunity. 
A large randomized, multicenter study carried out in 
over 1500 Italian children primed as infants with hex-
avalent vaccines 5 years earlier showed that 83.2% of 
those vaccinated with Infanrix Hexa maintained anti-
body over the protective level (≥ 10 mIU/ml) compared 
to 38.4% of those who were treated with Hexavac. Also 
GMC was higher in the former than in the latter group 
(61.3 mIU/ml vs 4.5 mIU/ml; p < 0.0001). Following a 
booster with a single dose of monovalent vaccine, both 
groups of vaccinees (either treated with Infanrix Hexa or 
with Hexavac) had similar good anamnestic responses 
both in terms of percentages of responders and GMCs, 
regardless of which hexavalent vaccine they had been 
primed with  [10]. These data were confirmed and ex-
tended by other studies [11, 12].
The conclusion from these data is that routine booster 
doses of vaccine do not seem necessary to sustain im-
munity in children primed with hexavalent vaccines, 
even though follow-up beyond 5 years is necessary to 
assess whether protection can last during adolescence 
and adulthood when risk behavior of exposure to HBV 
through sexual activity or intravenous drug-taking is ex-
pected to increase. 
A follow up study carried out in adolescents primed as 
infants 10 years before is currently in progress in Italy, 
and results will be available in 2015.
Are HBV-escape mutants a matter  
of concern?
Hepatitis B neutralizing (protective) antibodies (anti-
HBs) induced by vaccination are targeted largely to-
wards the amino acid hydrophilic region known as the 
common a determinant which is present on the outer 
protein coat or surface antigen (HBsAg), spanning ami-
no acids 124-147. This provides protection against all 
HBV genotypes (from A to H) and is responsible for 
the broad immunity afforded by hepatitis B vaccination. 
Thus, alterations of residues within this region of the 
surface antigen may determine conformational changes 
that can allow replication of the mutated HBV in vac-
cinated people.
An important mutation in the surface antigen region was 
identified in Italy some 25 years ago in infants born to 
HBsAg carrier mothers who developed breakthrough 
infections despite having received HBIG and vaccine 
at birth  [13-15]. This virus had a point mutation from 
guanosine to adenosine at nucleotide position 587, re-
sulting in aa substitution from glycine (G) to arginine 
(R) at position 145 in the a determinant. Since the G145R 
substitution alters the projecting loop (aa 139-147) of 
the a determinant, the neutralizing antibodies induced by 
vaccination are no longer able to recognize the mutated 
epitope. Besides G145R, other S-gene mutations poten-
tially able to evade neutralizing anti-HBs and infect vac-
cinated people have been described worldwide [16-19].
In addition, the emergence of polymerase mutants as-
sociated with resistance to treatment with nucleos(t)ide 
analogues can select viruses with crucial changes in the 
overlapping S-gene, potentially able to alter the S pro-
tein immunoreactivity [20-22]. Thus the increasing use 
of such drugs may cause the emergence of mutants po-
tentially able to escape vaccine-induced immunity and 
to infect vaccinees. 
Despite concern, at present the overall impact of such 
mutants seems to be low and they do not pose a public 
health threat or a need to modify the established hepati-
tis B vaccination programs. 
Is hepatitis B vaccination effective  
in preventing liver cancer?
Hepatocellular carcinoma (HCC) is one of the leading 
causes of cancer death in humans and hepatitis B virus 
(HBV) is the most common etiological cause of HCC 
in the world, particularly in Asia, the Middle East, Af-
rica and southern parts of Eastern and Central Europe. 
Chronic HBV infection can lead to chronic hepatitis, cir-
rhosis and HCC; it is estimated that chronic carriers of 
HBV are 100 times more likely to develop HCC than 
uninfected people. Thus prevention of chronic hepatitis 
B – through vaccination – can successfully prevent the 
risk of developing HBV-related cancer. Taiwan, a coun-
try where the universal HBV vaccination of newborns 
was implemented in 1984, is perhaps the best example 
of an area with previously high endemicity showing a 
substantial decrease over time of the burden of hepatitis 
B and HBV-related diseases, including HCC [23-26]. A 
study carried out by Chien et al, showed striking dif-
ferences in HCC incidence (0.293 vs 0.117 per 100,000 
person-years) between vaccinated and unvaccinated 
newborns 20 years after the implementation of vaccina-
tion, providing evidence that hepatitis B vaccination can 
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significantly prevent the long-term risk of HCC [27]. In 
Alaska, McMahon et al showed that following vaccina-
tion, the incidence of HCC in people < 20 years dropped 
from 3 per 100,00 in 1984-1988 to zero in 1995-1999, 
and no cases have occurred since 1999 [28].
All this clearly shows that anti-hepatitis B vaccination 
is a successful way to control and prevent HCC, indicat-
ing the hepatitis B vaccine as the first vaccine against a 
major human cancer. 
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